Merrimack halts pancreatic cancer trial

Merrimack Pharmaceuticals announced it will discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news